September 27, 2021 10:37 AM EDT

After pumping the brakes on their Angelman syndrome study, Ultragenyx and GeneTx are back in the race

Nicole DeFeudis

Editor

Eleven months after high doses of Ultragenyx and GeneTx’s Angelman syndrome candidate temporarily caused some patients to lose their ability to walk, the FDA is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After pumping the brakes on their Angelman syndrome study, Ultragenyx and GeneTx are back in the race

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Af­ter pump­ing the brakes on their An­gel­man syn­drome study, Ul­tragenyx and GeneTx are back in the race

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After pumping the brakes on their Angelman syndrome study, Ultragenyx and GeneTx are back in the race